🔎 Trials Near Me

홈 › 다발성 골수종 › 미시간

미시간의 다발성 골수종 임상 시험

다발성 골수종 관련 연구 26개가 미시간 내 여러 지역에서 참여자를 모집하고 있습니다.

미시간의 도시

공식 연구 텍스트(영어)

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

  • START Midwest /ID# 279035, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07409246

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Barbara Ann Karmanos Cancer Institute, Detroit
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05201781

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  • Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07393282

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • University of Michigan, Ann Arbor
  • Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
  • Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
  • 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05552222

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Karmanos Cancer Institute, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • University of Michigan Health System, Ann Arbor
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04634552

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Trinity Health Ann Arbor Hospital, Ann Arbor
  • Henry Ford Health Saint John Hospital, Detroit
  • Genesys Hurley Cancer Institute, Flint
  • 외 7개
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  • University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06953960

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  • Henry Ford Health System, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06980480

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  • GSK Investigational Site, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05714839

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • 외 36개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT04566328

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  • Research Site, Ann Arbor
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT06106945

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

  • Karmanos Cancer Institute, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06292780

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Ann Arbor
  • Research Site, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Karmanos Cancer Institute, Detroit
  • START Midwest, Grand Rapids
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07284758

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  • University of Michigan, Ann Arbor
  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 7. 1. 업데이트됨 · NCT06057402

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

  • Karmanos Cancer Institute, Detroit
  • KCI at McLaren Greater Lansing, Lansing
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 26. 업데이트됨 · NCT06107738

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Saint Joseph Mercy Hospital, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Saint Joseph Mercy Brighton, Brighton
  • 외 51개
피험자 모집 중3상
전 연령 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT05561387

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

  • Karmanos Cancer Institute, Detroit
  • START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT06433947

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

  • Karmanos Cancer Institute, Detroit
피험자 모집 중
18세 이상 · 모든 성별 · 2025. 8. 26. 업데이트됨 · NCT06908629

ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.